Quantcast

Latest Dipeptidyl peptidase-4 inhibitor Stories

2014-09-17 12:27:46

SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that as physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs. As the robust...

2014-08-15 23:00:59

The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of the diabetes treatments. New York, NY (PRWEB) August 15, 2014 Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits (http://www.byettalawsuit.com/) as well as several other medications, Bernstein Liebhard LLP reports....

2014-08-04 08:29:23

- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 4, 2014 /PRNewswire/ -- The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data that showed linagliptin co-administered with metformin provided statistically significant decreases in blood glucose compared with linagliptin alone in treatment-naive* adults with...

2014-06-15 16:20:24

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs. empagliflozin or linagliptin alone after 24 weeks RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 /PRNewswire/ -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly...

2014-06-09 08:29:57

· Data for investigational compounds LY2963016, empagliflozin and empagliflozin/linagliptin combination tablet highlight robust alliance pipeline RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company (NYSE: LLY) diabetes portfolio at the 74(th) American Diabetes Association (ADA) Scientific Sessions® in San Francisco, June 13-17....

2014-05-15 12:36:22

RIDGEFIELD, Conn. and INDIANAPOLIS, May 15, 2014 /PRNewswire/ -- Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announced. Additionally, similar proportions of patients in...

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...

2013-12-19 23:29:49

National network of lawyers will continue offer of these consultations through Christmas and New Year’s Day. Allegations involve links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancers. San Diego, CA (PRWEB) December 19, 2013 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about litigation...

2013-12-10 23:04:32

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'